Eli Lilly and Co
Novo Nordisk CEO testifies at Senate over weight loss drug prices
Novo Nordisk‘s top executive faces a Senate grilling on Tuesday over the high prices of the company’s weight loss drug ...
Why Eli Lilly and Palo Alto Networks are both up on news from their competitors
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time ...
FTC sues drug middlemen for allegedly inflating insulin prices
Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office ...
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of ...
57 million privately insured adults eligible for GLP-1s
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. ...
Eli Lilly could become the first $1 trillion healthcare stock
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. ...
We’re taking a nearly 300% profit on a hot drug stock
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, ...
Eli Lilly releases new, cheaper form of weight loss drug
Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly ...
Eli Lilly weight loss drug cuts risk of developing diabetes in trial
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March ...
Ro launches GLP-1 insurance coverage checker
Zoom In IconArrows pointing outwards The direct-to-consumer health-care startup Ro launched a new free tool Tuesday to help patients determine ...
